BRNO, Czech Republic, April 25,
2024 /PRNewswire/ -- Revvity's EUROIMMUN business, a
leading provider of high-quality in-vitro diagnostic products, and
ALPCO-GeneProof, a global leader in molecular diagnostics, jointly
announced a strategic partnership to enhance the availability of
GeneProof PCR kits throughout the European Union. This
collaboration brings together EUROIMMUN's extensive distribution
network and support infrastructure with ALPCO-GeneProof's
innovative molecular diagnostic technologies.
"Entering into the partnership with ALPCO-GeneProof, EUROIMMUN
is relying on an established and experienced provider for molecular
diagnostic assays. It will allow EUROIMMUN's customers to benefit
from a vastly expanded high-quality assay portfolio that can be run
on established real-time PCR cyclers," says Dirk Beecker, CEO of EUROIMMUN.
Erik Allen, CEO of
ALPCO-GeneProof, expressed confidence about the partnership,
stating, "Having EUROIMMUN as a partner brings a strong focus to
the European Union for the GeneProof products. Combining our
high-quality IVDR cleared kits with their expertise in the
diagnostic space and strong commercial presence means more
customers can access the fast-growing GeneProof infectious disease
assays."
The agreement will see EUROIMMUN delivering a comprehensive
portfolio of 42 molecular diagnostic assays from ALPCO-GeneProof.
These assays are based on the innovative "one workflow" technology,
which simplifies use and ensures compatibility with a broad range
of qPCR instruments. Additionally, EUROIMMUN will offer the croBEE®
nucleic acid extraction system, further enhancing the diagnostic
solutions.
The full menu of GeneProof PCR kits includes assays for
transplant and immunocompromised patients, sexually transmitted
infections (STIs), bloodborne pathogens, respiratory infections,
thrombotic mutations, neuroinfections, and antibiotic
resistance.
About ALPCO-GeneProof
ALPCO was founded in 1991 as an importer and distributor of
immunoassay-based products for the North American life science
markets. The company has since evolved into a leading producer of
novel immunodiagnostic reagents for specialty testing laboratories.
In 2022, ALPCO merged with GeneProof, a Czech Republic-based provider of specialty
molecular diagnostic solutions. Founded in 2005, GeneProof offers a
portfolio of more than 50 IVDD and 6 IVDR PCR test kits for
infectious diseases and genetic mutations, as well as a suite of
proprietary instrumentation for clinical laboratories of all sizes.
For additional information, please
visit www.alpco.com and www.geneproof.com.
About EUROIMMUN and Revvity
As one of the leading manufacturers of medical laboratory
diagnostics worldwide, EUROIMMUN stands for innovation. More than
3500 employees in 17 countries develop, produce and sell test
systems to support the diagnosis of diseases, as well as software
and automation solutions for the performance and evaluation of
these tests. Laboratories in over 140 countries use EUROIMMUN
products for the diagnosis of autoimmune and infectious diseases as
well as allergies, and to perform genetic analyses.
The company was founded in 1987 from the University of Lübeck
(Germany) and is part of Revvity,
Inc., located in Waltham,
Massachusetts. With revenues of more than $2.7 billion in 2023 and over 11,000 employees
worldwide, Revvity serves customers in pharmaceutical and biotech
companies, diagnostic labs, academia, and governments in more than
190 countries. It is included in the S&P 500 Index.
For more information, visit
https://www.euroimmun.com and https://www.revvity.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/revvitys-euroimmun-and-alpco-geneproof-announce-strategic-partnership-to-expand-ce-ivd-molecular-assay-offerings-302127658.html
SOURCE ALPCO-GeneProof